vimarsana.com
Home
Live Updates
ENHERTU® Demonstrated Statistically Significant and Cli
ENHERTU® Demonstrated Statistically Significant and Cli
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression
Plans for global regulatory...
Related Keywords
Jerusalem ,
Israel General ,
Israel ,
Daiichi Sankyo ,
National Cancer Institute ,
Daiichi Sankyo Inc ,
Low Metastatic Breast Cancer ,
Solid Tumors ,
Positive Locally Advanced ,
Metastatic Gastric Cancer ,
Adverse Reactions ,
Positive Metastatic Breast Cancer ,
Mutant Unresectable ,
Metastatic Solid Tumors ,
Reproductive Potential ,
Hepatic Impairment ,
Prescribing Information ,
Cancer Res ,
Stat Facts ,
Female Breast Cancer ,
Accessed April ,
Pathol Transl ,
Markets ,